Quest Diagnostics (DGX)
(Real Time Quote from BATS)
$137.60 USD
+0.90 (0.66%)
Updated Apr 24, 2024 02:20 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Price, Consensus and EPS Surprise
DGX 137.60 +0.90(0.66%)
Will DGX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DGX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DGX
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates
DGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Unlocking Q1 Potential of Quest Diagnostics (DGX): Exploring Wall Street Estimates for Key Metrics
Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to Decline
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
Other News for DGX
Quest Diagnostics price target raised by $5 at Truist, here's why
Quest Diagnostics price target raised by $11 at Deutsche Bank, here's why
The Analyst Landscape: 5 Takes On Quest Diagnostics
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Tactile Systems Technology (TCMD) and Danaher (DHR)
Quest Diagnostics price target raised by $7 at UBS, here's why